Actuate Therapeutics, Inc.
ACTUActuate Therapeutics, Inc. in brief
Actuate Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Fort Worth, Texas, USA. Its market value was $22 M on 30 October 2026, which makes it the 23,977th largest listed company in the world and the 4,125th largest in the USA on this site. It employs about 12 people. Its shares trade under the symbol ACTU (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Actuate Therapeutics, Inc.
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3. We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β and we believe elraglusib is one of the most advanced GSK-3β inhibitors in clinical development. Elraglusib was originally known as 9-ING-41 but was granted the elraglusib International Nonproprietary Names and United States Adopted Names generic name in 2021.
From the company's annual report filed with the US SEC: read the report
Actuate Therapeutics, Inc. timeline
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 🔔Initial public offeringFinal prospectus filed with the SEC on 13 August 2024; shares registered for exchange trading on 12 August 2024.
Events of Actuate Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,032 (Oct 2026) · #4,128 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 2.8×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -280.7%
- Liabilities / assets
- 43.5%
- Profit per employee
- $-1.9 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-23M | $-22M | — |
| Dec 2024 | — | — | $-25M | $-27M | — |
| Dec 2023 | — | — | $-25M | $-25M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-19M | — | — | $-1.06 | — |
| Dec 2024 | $-22M | — | — | $-3.26 | — |
| Dec 2023 | $-22M | — | — | $-17.24 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 30, 20268-KCurrent reportListing notice
- Oct 28, 20268-KCurrent reportMaterial agreement · Other events
- Oct 19, 2026S-1/AIPO registration (amended)
- Oct 14, 2026S-1/AIPO registration (amended)
- Oct 6, 2026S-1IPO registration
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 17, 20268-KCurrent reportListing notice
- May 22, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportRegulation FD disclosure
- May 6, 20268-KCurrent reportDirectors or officers changed · Other events
- Apr 6, 2026DEF 14AProxy statement
Official filings of Actuate Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-23 M
- Net income
- $-22 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $14 M
- Total liabilities
- $6 M
- Total equity
- $8 M
As of December-2025
Top 40 institutional investors in Actuate Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BIOS Capital Management, LP | 10,049,996 | 0 (0.00%) | 41.85% | $8 M | Nov 13, 2026 |
| 2 | Voss Capital, LP | 1,899,305 | +174,305 (+10.10%) | 7.91% | $1 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 393,433 | 0 (0.00%) | 1.64% | $0 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 104,315 | -8,239 (-7.32%) | 0.43% | $0 M | Nov 6, 2026 |
| 5 | Texas Capital Bank Wealth Management Services Inc | 102,612 | 0 (0.00%) | 0.43% | $0 M | Nov 9, 2026 |
| 6 | Palogic Value Management, L.P. | 100,000 | -100,000 (-50.00%) | 0.42% | $0 M | Nov 16, 2026 |
| 7 | Millennium Management LLC | 90,195 | -6,489 (-6.71%) | 0.38% | $0 M | Nov 16, 2026 |
| 8 | ABS Investment Management LLC | 73,186 | 0 (0.00%) | 0.30% | $0 M | Nov 16, 2026 |
| 9 | BlackRock, Inc. | 66,944 | -23,091 (-25.65%) | 0.28% | $0 M | Nov 13, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 54,497 | 0 (0.00%) | 0.23% | $0 M | Nov 13, 2026 |
| 11 | Rock Creek Group LLC | 50,000 | +10,737 (+27.35%) | 0.21% | $0 M | Nov 9, 2026 |
| 12 | Sfmg, LLC | 50,000 | +17,000 (+51.52%) | 0.21% | $0 M | Nov 13, 2026 |
| 13 | HighTower Advisors, LLC | 36,430 | -31 (-0.09%) | 0.15% | $0 M | Nov 10, 2026 |
| 14 | Susquehanna International Group, LLP | 25,076 | -3,106 (-11.02%) | 0.10% | $0 M | Nov 16, 2026 |
| 15 | Bridgeway Capital Management, LLC | 23,106 | -376 (-1.60%) | 0.10% | $0 M | Nov 16, 2026 |
| 16 | Empowered Funds, LLC | 23,106 | New | 0.10% | $0 M | Nov 13, 2026 |
| 17 | State Street Corp | 21,850 | 0 (0.00%) | 0.09% | $0 M | Nov 12, 2026 |
| 18 | Northern Trust Corp | 21,220 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 19 | Gleason Group, Inc. | 19,028 | 0 (0.00%) | 0.08% | $0 M | Oct 15, 2026 |
| 20 | Northwestern Mutual Wealth Management Co | 18,518 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 21 | LPL Financial LLC | 11,915 | -50 (-0.42%) | 0.05% | $0 M | Nov 6, 2026 |
| 22 | Sowell Financial Services LLC | 10,973 | 0 (0.00%) | 0.05% | $0 M | Oct 23, 2026 |
| 23 | Green Ridge Wealth Planning LLC | 10,000 | 0 (0.00%) | 0.04% | $0 M | Oct 8, 2026 |
| 24 | FNY Investment Advisers, LLC | 8,280 | New | 0.03% | $0 M | Oct 16, 2026 |
| 25 | Global Retirement Partners, LLC | 6,250 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
Show all 40: investors 26 to 40
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nuveen, LLC | 6,146 | New | 0.03% | $0 M | Nov 10, 2026 |
| 27 | Russell Investments Group, Ltd. | 5,932 | +5,259 (+781.43%) | 0.02% | $0 M | Nov 6, 2026 |
| 28 | Vanguard Global Advisers, LLC | 5,102 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 29 | UBS Group AG | 2,707 | -827 (-23.40%) | 0.01% | $0 M | Nov 10, 2026 |
| 30 | Wells Fargo & Company/mn | 2,440 | -6 (-0.25%) | 0.01% | $0 M | Nov 16, 2026 |
| 31 | Morgan Stanley | 2,147 | -1,343 (-38.48%) | 0.01% | $0 M | Nov 13, 2026 |
| 32 | Royal Bank Of Canada | 1,332 | +849 (+175.78%) | 0.01% | $0 M | Nov 16, 2026 |
| 33 | Osaic Holdings, Inc. | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | BNP Paribas Financial Markets | 690 | -300 (-30.30%) | 0.00% | $0 M | Nov 12, 2026 |
| 35 | FMR LLC | 28 | -3,259 (-99.15%) | 0.00% | $0 M | Nov 10, 2026 |
| 36 | IFP Advisors, Inc | 26 | -47 (-64.38%) | 0.00% | $0 M | Oct 16, 2026 |
| 37 | Tower Research Capital LLC (TRC) | 17 | -3,617 (-99.53%) | 0.00% | $0 M | Nov 16, 2026 |
| 38 | EverSource Wealth Advisors, LLC | 2 | -263 (-99.25%) | 0.00% | $0 M | Nov 4, 2026 |
| 39 | Barclays PLC | 1 | -420 (-99.76%) | 0.00% | $0 M | Nov 6, 2026 |
| 40 | Caitong International Asset Management Co., Ltd | 1 | New | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Actuate Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 287,385 | $0 M | 1.2% | <0.01% | +1250% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 106,048 | $0 M | 0.44% | <0.01% | +1245% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 51,919 | $0 M | 0.22% | <0.01% | +10.0% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 48,395 | $0 M | 0.20% | <0.01% | +4.0% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 38,230 | $0 M | 0.16% | <0.01% | +2204% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 23,482 | $0 M | 0.10% | 0.02% | +923% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 15,885 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,591 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 12,252 | $0 M | 0.05% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 13,249 | $0 M | 0.06% | <0.01% | −4.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 8,845 | $0 M | 0.04% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 5,490 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 5,506 | $0 M | 0.02% | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,738 | $0 M | <0.01% | <0.01% | +1250% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,700 | $0 M | <0.01% | <0.01% | +1250% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 755 | $0 M | <0.01% | <0.01% | −0.0% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 448 | $0 M | <0.01% | <0.01% | +8.7% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 350 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 351 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 421 | $0 M | <0.01% | <0.01% | −0.5% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 239 | $0 M | <0.01% | <0.01% | −1.8% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 108 | $0 M | <0.01% | <0.01% | +2.7% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 108 | $0 M | <0.01% | <0.01% | +3.4% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 46 | $0 M | <0.01% | <0.01% | +4.4% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 54 | $0 M | <0.01% | <0.01% | +1485% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 55 | $0 M | <0.01% | <0.01% | +4.4% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 75 | $0 M | <0.01% | <0.01% | +3.7% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 92 | $0 M | <0.01% | <0.01% | +3.2% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 28 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Actuate Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Daniel M. SchmittPresident, CEO and Director, Director | Buy | +140,844 | $0.355 | $50 K | 442,560 | Form 4 |
| filed | Daniel M. SchmittPresident, CEO and Director, Director | Option exercise | +272,056 | — | — | 422,237 | Form 4 |
| filed | Daniel M. SchmittPresident, CEO and Director, Director | Shares withheld for tax | -120,521 | $1.010 | $122 K | 301,716 | Form 4 |
| filed | Daniel M. SchmittPresident, CEO and Director, Director | Option exercise | +272,055 | — | — | 272,055 | Form 4 |
| filed | Daniel M. SchmittPresident, CEO and Director, Director | Shares withheld for tax | -121,874 | $4.330 | $528 K | 150,181 | Form 4 |
| filed | Todd S. ThomsonDirector, 10% owner | Sellindirect | -280,000 | $5.800 | $1.6 M | 904,795 | Form 4 |
| filed | BIOS Actuate Co-Invest I, LPDirector, 10% owner | Buyindirect | +71,428 | $7.000 | $500 K | 196,428 | Form 4 |
| filed | BIOS Fund II, LPDirector, 10% owner | Buyindirect | +71,428 | $7.000 | — | 196,428 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Actuate Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 61,372 shares at $0.37
- : 14,998 shares at $0.38
- : 23,484 shares at $0.40
- : 3,139 shares at $0.48
- : 28,495 shares at $0.52
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Actuate Therapeutics, Inc. scorecard#
Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.8×Price to book 2.8× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.06 vs -3.26Diluted EPS -1.06 in fiscal 2025 against -3.26 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-554.4%-554.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year151.1%Diluted shares up 151.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Actuate Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | 10−44.9%— | 19−14.0%— | 22—— | |
| General and administrative | 12+88.2%— | 6.5+98.6%— | 3.3—— | |
| Operating expenses | 22−10.6%— | 25+0.7%— | 25—— | |
| Operating income | −22—— | −25—— | −25—— | |
| Interest and finance income | 0.3+29.4%— | 0.2−37.0%— | 0.4—— | |
| Interest expense and finance costs | 0.0+8.2%— | 0.0−57.1%— | 0.0—— | |
| Other non-operating income (expense) | 0.3—— | −2.1−1027%— | 0.2—— | |
| Income tax | 0.00.0%— | 0.0—— | 0—— | |
| Net income attributable to shareholders | −22—— | −27—— | −25—— | |
| Earnings per share, basic | -1.06—— | -3.26—— | -17.24—— | |
| Earnings per share, diluted | -1.06—— | -3.26—— | -17.24—— | |
| Shares, weighted average (basic) | 21+151%— | 8.4+483%— | 1.4—— | |
| Shares, weighted average (diluted) | 21+151%— | 8.4+483%— | 1.4—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 13+52.3%93.8% | 8.6+192%92.7% | 3.0—98.8% | |
| Other current assets | 0.5−14.5%3.4% | 0.6+1434%6.1% | 0.0—1.2% | |
| Current assets | 14+48.2%97.2% | 9.2+207%98.8% | 3.0—100% | |
| Total assets | 14+50.6%100% | 9.3+211%100% | 3.0—100% | |
| Accounts payable | 1.5−20.7%10.9% | 1.9−43.9%20.6% | 3.4—114% | |
| Current liabilities | 5.7−35.2%40.7% | 8.8+27.2%94.5% | 6.9—231% | |
| Non-current liabilities | 0.4−1.6%2.9% | 0.4−73.0%4.4% | 1.5—50.8% | |
| Total liabilities | 6.1−33.7%43.5% | 9.2+9.1%98.9% | 8.4—282% | |
| Retained earnings | −155—−1102% | −132—−1421% | −105—−3508% | |
| Shareholders' equity | 7.9+7506%56.5% | 0.1—1.1% | −100—−3326% | |
| Total liabilities and equity | 14+50.6%100% | 9.3+211%100% | 3.0—100% | |
| Shares outstanding | 23+19.0%— | 20+1055%— | 1.7—— | |
| Cash-flow statement | ||||
| Share-based compensation | 6.0+203%— | 2.0+371%— | 0.4—— | |
| Cash from operating activities | −19—— | −22—— | −22—— | |
| Shares issued | 3.8—— | 0—— | — | |
| Cash from financing activities | 24−13.8%— | 28+566%— | 4.1—— | |
| Report | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||
| Research and development | 8.6−27.6%— | 1.8−16.8%— | 2.1−25.2%— | 2.6−20.3%— | 2.1*−42.2%— | 2.2−42.0%— | 2.8−36.8%— | 3.2—— | 3.7*—— | 3.8—— | 4.4—— | |
| General and administrative | 10−18.8%— | 1.6−50.6%— | 2.8−11.4%— | 3.1−0.1%— | 2.6*−10.9%— | 3.3+101%— | 3.2+202%— | 3.1—— | 2.9*—— | 1.6—— | 1.1—— | |
| Operating expenses | 19−23.1%— | 3.4−37.2%— | 4.9−17.8%— | 5.7−10.4%— | 4.7*−28.5%— | 5.5+1.5%— | 6.0+9.8%— | 6.4—— | 6.6*—— | 5.4—— | 5.4—— | |
| Operating income | −19—— | −3.4—— | −4.9—— | −5.7—— | −4.7*—— | −5.5—— | −6.0—— | −6.4—— | −6.6*—— | −5.4—— | −5.4—— | |
| Interest and finance income | — | — | 0.0+83.5%— | 0.1+59.0%— | 0.1*+18.2%— | 0.1−13.3%— | 0.0+184%— | 0.1—— | 0.1*—— | 0.1—— | 0.0—— | |
| Interest expense and finance costs | 0.0−0.1%— | 0.00.0%— | 0.0+0.0%— | 0.0−0.0%— | 0.0*−0.3%— | 0.0+45.1%— | 0.0−0.3%— | 0.0—— | 0.0*—— | 0.0—— | 0.0—— | |
| Other non-operating income (expense) | 0.3+11.0%— | 0.0−71.6%— | 0.0+105%— | 0.1+65.2%— | 0.1*+19.0%— | 0.1—— | 0.0—— | 0.0—— | 0.1*—— | −0.6—— | −1.1—— | |
| Net income attributable to shareholders | −18—— | −3.4—— | −4.9—— | −5.6—— | −4.6*—— | −5.4—— | −5.9—— | −6.3—— | −6.4*—— | −6.0—— | −6.6—— | |
| Earnings per share, basic | — | -0.14—— | -0.20—— | -0.24—— | — | -0.25—— | -0.30—— | -0.32—— | — | -0.55—— | -4.20—— | |
| Earnings per share, diluted | — | -0.14—— | -0.20—— | -0.24—— | — | -0.25—— | -0.30—— | -0.32—— | — | -0.55—— | -4.20—— | |
| Shares, weighted average (basic) | 24+13.2%— | 24+13.2%— | 24+21.5%— | 24+20.7%— | — | 21+98.6%— | 20+1155%— | 19—— | — | 11—— | 1.6—— | |
| Shares, weighted average (diluted) | 24+13.2%— | 24+13.2%— | 24+21.5%— | 24+20.7%— | — | 21+98.6%— | 20+1155%— | 19—— | — | 11—— | 1.6—— | |
| Balance sheet | ||||||||||||
| Cash and cash equivalents | 2.1—65.3% | 2.1−87.6%65.3% | 4.4−31.8%85.1% | 8.1+109%91.3% | 13+52.3%93.8% | 17+25.2%95.5% | 6.5+1746%93.2% | 3.9—86.8% | 8.6—92.7% | 14—94.8% | 0.4—20.3% | |
| Other current assets | 0.5—17.0% | 0.5+5.2%17.0% | 0.3+64.4%6.2% | 0.4+7.3%4.3% | 0.5−14.5%3.4% | 0.5−29.8%2.9% | 0.2−1.0%2.8% | 0.4—8.0% | 0.6—6.1% | 0.7—5.2% | 0.2—11.4% | |
| Current assets | 2.6—82.3% | 2.6−84.8%82.3% | 4.7−29.0%91.3% | 8.5+101%95.6% | 14+48.2%97.2% | 17+22.3%98.5% | 6.7+1117%96.0% | 4.2—94.8% | 9.2—98.8% | 14—100% | 0.5—31.8% | |
| Total assets | 3.2—100% | 3.2−81.8%100% | 5.2−25.4%100% | 8.9+98.8%100% | 14+50.6%100% | 18+24.2%100% | 7.0+303%100% | 4.5—100% | 9.3—100% | 14—100% | 1.7—100% | |
| Accounts payable | 0.9—27.7% | 0.9−28.5%27.7% | 1.1−66.0%20.7% | 1.2−54.6%13.5% | 1.5−20.7%10.9% | 1.2−46.6%7.0% | 3.2−46.2%45.5% | 2.6—59.0% | 1.9—20.6% | 2.3—16.3% | 5.9—340% | |
| Current liabilities | 3.6—113% | 3.6−43.2%113% | 3.8−58.6%73.2% | 4.7−48.4%53.0% | 5.7−35.2%40.7% | 6.4−25.0%36.0% | 9.2−54.2%132% | 9.2—204% | 8.8—94.5% | 8.5—59.6% | 20—1160% | |
| Non-current liabilities | 0.4—12.6% | 0.40.0%12.6% | 0.4−4.0%7.8% | 0.4−2.8%4.5% | 0.4−1.6%2.9% | 0.4−0.4%2.3% | 0.4−75.7%6.1% | 0.4—9.3% | 0.4—4.4% | 0.4—2.9% | 1.7—100% | |
| Total liabilities | 4.0—125% | 4.0−40.6%125% | 4.2−56.2%81.0% | 5.1−46.4%57.5% | 6.1−33.7%43.5% | 6.8−23.9%38.3% | 9.6−55.9%138% | 9.6—213% | 9.2—98.9% | 8.9—62.4% | 22—1260% | |
| Retained earnings | −169—−5236% | −169—−5236% | −165—−3175% | −160—−1798% | −155—−1102% | −150—−847% | −145—−2076% | −139—−3094% | −132—−1421% | −126—−883% | −120—−6931% | |
| Shareholders' equity | −0.8—−25.1% | −0.8−107%−25.1% | 1.0—19.0% | 3.8—42.5% | 7.9+7506%56.5% | 11+104%61.7% | −2.7—−38.1% | −5.1—−113% | 0.1—1.1% | 5.4—37.6% | −114—−6601% | |
| Total liabilities and equity | 3.2—100% | 3.2−81.8%100% | 5.2−25.4%100% | 8.9+98.8%100% | 14+50.6%100% | 18+24.2%100% | 7.0+303%100% | 4.5—100% | 9.3—100% | 14—100% | 1.7—100% | |
| Shares outstanding | 25—— | 25+6.5%— | 24+17.3%— | 24+21.4%— | 23+19.0%— | 23+19.0%— | 20+1111%— | 20—— | 20—— | 20—— | 1.7—— | |
| Cash-flow statement | ||||||||||||
| Share-based compensation | 5.2−8.5%— | 1.0−46.1%— | 1.3−15.1%— | 1.4+20.6%— | 1.5*+29.4%— | 1.8+218%— | 1.6+1654%— | 1.1—— | 1.2*—— | 0.6—— | 0.1—— | |
| Cash from operating activities | −16—— | −3.0*—— | −4.4*—— | −5.0—— | −3.7*—— | −6.7*—— | −4.2*—— | −4.6—— | −4.8*—— | −9.1*—— | — | |
| Shares issued | 5.9—— | 0.8*—— | 0.7*—— | 0.5—— | 3.8r0*—— | 0r1.7*—— | 0r2.2*—— | 0—— | 0*—— | 0*—— | — | |
| Cash from financing activities | 1.3−94.6%— | 0.6*−96.3%— | 0.7*−89.7%— | −0.0—— | −0.0*—— | 17*−23.3%— | 6.8*—— | −0.1—— | −0.1*—— | 22*—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Actuate Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Actuate Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Directors and officers 2 · Material agreement 5 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Auditor changed | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 30, 2026
Acquisitions and funding#
7 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $5 M | Private placement after listing | $2 to $10 million | 8 | equity, options | SEC |
| Feb 2024 | $3 M | No. 7 | $2 to $10 million | 1 | debt, options | SEC |
| Sep 2022 | $19 M | No. 6 | $10 to $50 million | 95 | equity | SEC |
| Nov 2020 | $14 M | No. 5 | $10 to $50 million | 14 | equity | SEC |
| Oct 2019 | $7 M | No. 4 | $2 to $10 million | 17 | equity, options | SEC |
| Apr 2019 | $22 M | No. 3 | $10 to $50 million | 21 | equity, options | SEC |
| Aug 2018 | $4 M | No. 2 | $2 to $10 million | 18 | debt, options | SEC |
| Mar 2017 | $3 M | No. 1 | $2 to $10 million | 2 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Actuate Therapeutics, Inc. compares in Biotechnology
- Market cap$22 M · higher than 18% of 726
- Price / book2.8× · lower than 50% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Actuate Therapeutics, Inc.🇺🇸 | $22 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Actuate Therapeutics, Inc.? Verify and update this profile — free
Show Actuate Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.